Aktuellt
SENASTE
Redeye endorses Spago reporting clear contrast enhancement in the second SPAGOPIX-01 cohort, confirming positive interim results from the first cohort. Further, the company has plans to expand the study into documented pancreatic cancer with liver metastases. Today’s positive readout is in line with our expectations, and we reiterate our view that Spago has a bright future.
LÄS MER
